Arecor Therapeutics PLC (AIM:AREC) chief executive Sarah Howell speaks to Proactive following the publication of new study data for its lead product AT247, an ultra-rapid-acting form of insulin.
Howell suggests that the study indicates that Arecor may have created an insulin that can be absorbed more quickly into the body than any existing rival product.
A sufficiently quickly-to-absorb form of insulin has until now been the sole remaining missing component of a useable artificial pancreas system.